Editas Medicine Inc. (EDIT) Soars 5.29% on December 03

Equities Staff  |

Editas Medicine Inc. (EDIT) had a good day on the market for Thursday December 03 as shares jumped 5.29% to close at $33.23. About 1.37 million shares traded hands on 14,337 trades for the day, compared with an average daily volume of n/a shares out of a total float of 62.33 million. After opening the trading day at $31.77, shares of Editas Medicine Inc. stayed within a range of $34.29 to $31.42.

With today's gains, Editas Medicine Inc. now has a market cap of $2.07 billion. Shares of Editas Medicine Inc. have been trading within a range of $39.96 and $14.02 over the last year, and it had a 50-day SMA of $n/a and a 200-day SMA of $n/a.

Editas Medicine Inc is a US-based genome editing company. It is engaged in treating patients with genetically defined diseases by correcting disease-causing genes. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company only operating segment being developing and commercializing genome editing technology.

Editas Medicine Inc. is based out of Cambridge, MA and has some 208 employees. Its CEO is Cynthia Collins.

For a complete fundamental analysis of Editas Medicine Inc., check out Equities.com’s Stock Valuation Analysis report for EDIT.

Still paying commissions on stock trades? Equities.com now offers $7.99/month unlimited trading and flat-fee options trading for $89.99/month! Get started today by https://www.equities.com/trading-start

Editas Medicine Inc. is also a component of the Russell 2000. The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.

Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.

To get more information on Editas Medicine Inc. and to follow the company’s latest updates, you can visit the company’s profile page here: EDIT’s Profile. For more news on the financial markets and emerging growth companies, be sure to visit Equities.com’s Newsdesk. Also, don’t forget to sign-up for our daily email newsletter to ensure you don’t miss out on any of our best stories.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer



Symbol Last Price Change % Change